With the acquisition, Interlace’s operations will be integrated within Hologic’s GYN Surgical Products division and
The acquisition expands Hologic’s portfolio of non-invasive, gynecological solutions with MyoSure System for removing intracavitary fibroids and polyps.
GYN Surgical Products senior vice president and general manager Steve Williamson said that the acquisition of Interlace is consistent with their strategy to strengthen their position in women’s healthcare.
"MyoSure is an innovative technology that is designed to safely and easily remove fibroids and polyps that plague millions of women and it is a natural extension of their OB/GYN product portfolio which provides women with minimally-invasive treatment options – from their child bearing years to menopause," Williamson said.
"The strong clinical performance and ease of use of the MyoSure device make it a natural fit with our NovaSure endometrial ablation and Adiana permanent contraception product lines."
